Inovio Pharmaceuticals, Inc.
INO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.02 | -0.00 | -1.29 |
| FCF Yield | -210.37% | -91.88% | -58.34% | -1.69% |
| EV / EBITDA | 0.04 | -1.16 | -1.32 | -43.21 |
| Quality | ||||
| ROIC | -0.13% | -97.55% | -104.81% | -69.28% |
| Gross Margin | -1,337.41% | -321.09% | 46.44% | -166.56% |
| Cash Conversion Ratio | 0.97 | 0.92 | 0.77 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | -72.32% | -22.32% | 11.46% | -24.43% |
| Free Cash Flow Growth | 16.14% | 42.59% | -0.11% | -20.86% |
| Safety | ||||
| Net Debt / EBITDA | 0.52 | -0.12 | 0.05 | 0.13 |
| Interest Coverage | -632.05 | -117.71 | -213.38 | -155.55 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 1,258.55 | 570.90 | -982.66 | -506.33 |